Gene polymorphism of serotonin receptors and drug-induced hyperprolactinemia in schizophrenic patients

Osmanova, D. Z., Boiko, A. S., Fedorenko, O. Y., Pozhidaev, I. V., Freidin, M. B., Kornetova, E. G., Ivanova, S. A., Wilffert, B. & Loonen, A. J. M. Oct-2016 In : European Neuropsychopharmacology. 26, Supplement 2, p. S515-S516 2 p.

Research output: Other research outputMeeting Abstract

Original languageEnglish
Pages (from-to)S515-S516
Number of pages2
JournalEuropean Neuropsychopharmacology
Issue numberSupplement 2
StatePublished - Oct-2016
Event29th Congress of the European-College-of-Neuropsychopharmacology (ECNP) - Vienna, Austria


29th Congress of the European-College-of-Neuropsychopharmacology (ECNP)


Vienna, Austria

Event: Conference


  • atypical antipsychotic agent, dopamine 2 receptor, endogenous compound, prolactin, serotonin 1A receptor, serotonin 1B receptor, serotonin 2A receptor, serotonin 2C receptor, serotonin 3A receptor, serotonin 3B receptor, serotonin 6 receptor, adult, adverse drug reaction, chemical binding, chi square test, controlled study, data analysis software, diagnosis, DNA polymorphism, drug therapy, enzyme linked immunosorbent assay, female, gene activation, gene frequency, gene inactivation, gene mutation, genetic marker, genetic susceptibility, genetic variability, hemizygote, human, hyperprolactinemia, hypophysis, major clinical study, male, modulation, prolactin blood level, prolactin release, psychosis, Russian (citizen), side effect

View graph of relations

ID: 39446542